Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Suizenji in Unresectable Pancreatic Ductal Adenocarcinoma
NCT07033689Phase 1Recruiting
- Sponsor
- SONIRE Therapeutics
- Start
- Jan 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in pancreatic ductal adenocarcinoma (PDAC), sponsored by SONIRE Therapeutics. Primary endpoint: Technical success for device feasibility at 3 months. Started Jan 2026; status: recruiting.
02
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07033689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07033689.